簇集蛋白在心血管疾病中的研究进展

doi:10.3969/j.issn.1004-583X.2022.09.016

摘要/Abstract

摘要：

簇集蛋白(clusterin,CLU),又称为载脂蛋白J,是一种新型脂肪因子。可在多种组织中表达,如心脏、胰腺、肾脏、脑、睾丸、前列腺等,并参与机体的脂质转运、细胞凋亡、氧化应激、炎症反应等过程。与心血管疾病、肥胖相关代谢性疾病、肿瘤、神经退行性病变等相关,并与疾病严重程度有一定的关系,提示CLU可能在疾病进展过程中发挥一定的保护作用,因此CLU有可能成为上述疾病潜在的预测因子。本文就CLU在心血管疾病中的研究进展进行综述,旨在为临床提供依据。

关键词: 心血管疾病, 冠心病, 心力衰竭, 高血压, 心肌疾病, 聚集素

中图分类号:

王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.09.016

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I9/842

参考文献 45

[1]	Lau WB, Ohashi K, Wang Y, et al. Role of adipokines in cardiovascular disease[J]. Circ J, 2017, 81(7):920-928. doi: 10.1253/circj.CJ-17-0458 pmid: 28603178
[2]	Recinella L, Orlando G, Ferrante C, et al. Adipokines:New potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases[J]. Front Physiol, 2020, 11: 578966. doi: 10.3389/fphys.2020.578966 URL
[3]	Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone[J]. Trends Biochem Sci, 2000, 25(3):95-98. pmid: 10694874
[4]	Wittwer J, Bradley D. Clusterin and its role in insulin resistance and the cardiometabolic syndrome[J]. Front Immunol, 2021, 12:612496. doi: 10.3389/fimmu.2021.612496 URL
[5]	Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid[J]. J Biol Chem, 1983, 258(12):7714-7720. pmid: 6863260
[6]	卜浩. sCLU在胰腺癌组织中的表达与其临床意义研究[D]. 湖南师范大学, 2020.
[7]	Park S, Mathis KW, Lee IK. The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases[J]. Rev Endocr Metab Disord, 2014, 15(1):45-53. doi: 10.1007/s11154-013-9275-3 URL
[8]	Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases[J]. Free Radic Res, 2006, 40(12):1324-1334. doi: 10.1080/10715760600902310 URL
[9]	Boel N, Edkins A. Regulation of the extracellular matrix by heat shock proteins and molecular chaperones[J]. Heat Shock Prot Imm Syst, 2018:97-121.
[10]	Cunin P, Beauvillain C, Miot C, et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses[J]. Cell Death Dis, 2016, 7(5): e2215.
[11]	Hong SW, Lee J, Kim MJ, et al. Clusterin protects lipotoxicity-induced apoptosis via upregulation of autophagy in insulin-secreting cells[J]. Endocrinol Metab (Seoul), 2020, 35(4):943-953. doi: 10.3803/EnM.2020.768 URL
[12]	Lee J, Hong SW, Kwon H, et al. Resveratrol, an activator of SIRT1, improves ER stress by increasing clusterin expression in HepG2 cells[J]. Cell Stress Chaperones, 2019, 24(4):825-833. doi: 10.1007/s12192-019-01012-z URL
[13]	Xiao Y, Zeng M, Yin L, et al. Clusterin increases mitochondrial respiratory chain complex I activity and protects against hexavalent chromium-induced cytotoxicity in L-02 hepatocytes[J]. Toxicol Res, 2018, 8(1):15-24. doi: 10.1039/C8TX00231B URL
[14]	Ma Y, Li S, Tang S, et al. Clusterin protects against Cr(VI)-induced oxidative stress-associated hepatotoxicity by mediating the Akt-Keap1-Nrf2 signaling pathway[J]. Environ Sci Pollut Res Int, 2022, 29(34):52289-52301. doi: 10.1007/s11356-022-19118-w URL
[15]	Zhang Y, Zhang Y, Xiao Y, et al. Expression of clusterin suppresses Cr(VI)-induced premature senescence through activation of PI3K/AKT pathway[J]. Ecotoxicol Environ Saf, 2019, 183:109465. doi: 10.1016/j.ecoenv.2019.109465 URL
[16]	Li Y, Song YQ, Zhang Y, et al. Over-expression of apolipoprotein J inhibits cholesterol crystal-Induced inflammatory responses via suppressing NLRP3 inflammasome activation in THP-1 macrophages[J]. Folia Biol (Praha), 2021, 67(5-6):183-190.
[17]	Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti-and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling[J]. Circulation, 2013, 127(8):891-904. doi: 10.1161/CIRCULATIONAHA.112.108753 URL
[18]	Iłżecka J, Iłżecki M, Grabarska A, et al. Clusterin as a potential marker of brain ischemia-reperfusion injury in patients undergoing carotid endarterectomy[J]. Ups J Med Sci, 2019, 124(3):193-198. doi: 10.1080/03009734.2019.1646359 URL
[19]	Zhu H, Liu M, Zhai T, et al. High serum clusterin levels are associated with premature coronary artery disease in a Chinese population[J]. Diabetes Metab Res Rev, 2019, 35(4):e3128. doi: 10.1002/dmrr.3128 URL
[20]	Kang M, Seong Y, Mahmud J, et al. Obscurin and Clusterin Elevation in Serum of Acute Myocardial Infarction Patients[J]. Bull Korean Chem Soc, 2020, 41(3):266-273. doi: 10.1002/bkcs.11955 URL
[21]	Traxler D, Spannbauer A, Einzinger P, et al. Early elevation of systemic plasma clusterin after reperfused acute myocardial infarction in a preclinical porcine model of ischemic heart disease[J]. Int J Mol Sci, 2020, 21(13):4591. doi: 10.3390/ijms21134591 URL
[22]	Wu D, Zhang K, Hu P. The role of autophagy in acute myocardial infarction[J]. Front Pharmacol, 2019, 10:551. doi: 10.3389/fphar.2019.00551 pmid: 31214022
[23]	Turkieh A, Porouchani S, Beseme O, et al. Increased clusterin levels after myocardial infarction is due to a defect in protein degradation systems activity[J]. Cell Death Dis, 2019, 10(8): 608. doi: 10.1038/s41419-019-1857-x pmid: 31406108
[24]	Pavo N, Lukovic D, Zlabinger K, et al. Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion[J]. Oncotarget, 2017, 8(40) : 67227-67240. doi: 10.18632/oncotarget.18438 pmid: 28978029
[25]	梁鹏. 急性冠脉综合征患者血清簇集蛋白水平与冠脉狭窄程度相关性研究[D]. 河北医科大学, 2019.
[26]	Eggers KM, Lindhagen L, Baron T, et al. Erratum to: Predicting outcome in acute myocardial infarction: An analysis investigating 175 circulating biomarkers[J]. Eur Heart J Acute Cardiovasc Care, 2022, 11(1):88. doi: 10.1093/ehjacc/zuab107 URL
[27]	Bass-Stringer S, Ooi JYY, McMullen JR. Clusterin is regulated by IGF1-PI3K signaling in the heart: Implications for biomarker and drug target discovery, and cardiotoxicity[J]. Arch Toxicol, 2020, 94:1763-1768. doi: 10.1007/s00204-020-02709-2 pmid: 32172307
[28]	Koller L, Richter B, Winter MP, et al. Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure[J]. Clin Lipidol, 2017, 11(1):178-184.
[29]	Turkieh A, Fertin M, Bouvet M, et al. Expression and implication of clusterin in left ventricular remodeling after myocardial infarction[J]. Circ Heart Fail, 2018, 11(6):e004838. doi: 10.1161/CIRCHEARTFAILURE.117.004838 URL
[30]	Sirtori CR, Ruscica M, Calabresi L, et al. HDL therapy today: From atherosclerosis, to stent compatibility to heart failure[J]. Ann Med, 2019, 51(7-8):345-359. doi: 10.1080/07853890.2019.1694695 pmid: 31729238
[31]	Jenča D, Melenovský V, Stehlik J, et al. Heart failure after myocardial infarction: Incidence and predictors[J]. ESC Heart Fail, 2020, 8(1):222-237.
[32]	杨斐然. 原发性老年高血压患者血清簇集蛋白水平与血管内皮功能的相关性[D]. 河北医科大学, 2019.
[33]	Zeng S, Han M, Jiang M, et al. Serum complement proteomics reveal biomarkers for hypertension disorder of pregnancy and the potential role of clusterin[J]. Reprod Biol Endocrinol, 2021, 19(1):56. doi: 10.1186/s12958-021-00742-z URL
[34]	Kocatürk M, Baykal AT, Turkseven S, et al. Evaluation of serum and ascitic fluid proteomes in dogs with dilated cardiomyopathy[J]. Kafkas Uni Vet Fak Derg, 2016, 22: 273-279.
[35]	Roura S, Gámez-Valero A, Lupón J, et al. Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy[J]. Lab Invest, 2018, 98(10):1291-1299. doi: 10.1038/s41374-018-0044-5 pmid: 29540862
[36]	Kourelis TV, Dasari SS, Dispenzieri A, et al. A proteomic atlas of cardiac amyloid plaques[J]. JACC Cardio Oncol, 2020, 2(4):632-643.
[37]	McLaughlin L, Zhu G, Mistry M, et al. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis[J]. Clin Invest, 2000, 106(9):1105-1113. doi: 10.1172/JCI9037 URL
[38]	Pereira RM, Mekary RA, da Cruz Rodrigues KC, et al. Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes[J]. Heart Fail Rev, 2018, 23(1):123-129. doi: 10.1007/s10741-017-9654-z pmid: 28948410
[39]	Guan Q, Li S, Yip G, et al. Decrease in donor heart injury by recombinant clusterin protein in cold preservation with University of Wisconsin solution[J]. Surgery, 2012, 151(3):364-371. doi: 10.1016/j.surg.2011.09.032 URL
[40]	Du J, Liu L, Yu B, et al. Clusterin (apolipoprotein J) facilitates NF-κB and Bax degradation and prevents I/R injury in heart transplantation[J]. Int J Clin Exp Pathol, 2018, 11(3):1186-1196.
[41]	Hollander Z, Lazárová M, Lam KK, et al. Proteomic biomarkers of recovered heart function[J]. Eur J Heart Fail, 2014, 16:551-559. doi: 10.1002/ejhf.65 pmid: 24574204
[42]	Oh GS, Yoon J, Kim G, et al. Regulation of adipocyte differentiation by clusterin-mediated Krüppel-like factor 5 stabilization[J]. FASEB J, 2020, 34(12): 16276-16290. doi: 10.1096/fj.202000551RR URL
[43]	Peng M, Deng J, Zhou S, et al. The role of clusterin in cancer metastasis[J]. Cancer Manag Res, 2019, 11:2405-2414. doi: 10.2147/CMAR.S196273 pmid: 31114318
[44]	Wilson MR, Zoubeidi A. Clusterin as a therapeutic target[J]. Expert Opin Ther Targets, 2017, 21(2):201-213. doi: 10.1080/14728222.2017.1267142 URL
[45]	Foster EM, Dangla-Valls A, Lovestone S, et al. Clusterin in Alzheimer's disease: Mechanisms, genetics, and lessons from other pathologies[J]. Front Neurosci, 2019, 13:164. doi: 10.3389/fnins.2019.00164 URL

簇集蛋白在心血管疾病中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马丽娜, 焦焕利, 曹振华. 慢性非缺血性心功能衰竭合并血栓栓塞及药物治疗研究进展[J]. 临床荟萃, 2024, 39(1): 75-79.
[2]	段芳, 崔炜. 血管扩张剂在急性心力衰竭救治中的应用原则[J]. 临床荟萃, 2023, 38(9): 773-778.
[3]	魏宇涵, 赵亚楠, 张桂彬, 吴雨晴, 董博华, 扈家源, 杨文琦. 单核细胞/高密度脂蛋白胆固醇比值、红细胞分布宽度、尿酸与冠心病患者冠状动脉病变严重程度的相关性[J]. 临床荟萃, 2023, 38(9): 796-801.
[4]	赵浩天, 李丽. 肺超声在心脏急重症疾病合并肺水肿中应用的研究进展[J]. 临床荟萃, 2023, 38(9): 832-837.
[5]	顾天舒, 梁雪, 蔡嘉庚, 李广平. m6A RNA甲基化修饰在心血管疾病中的进展[J]. 临床荟萃, 2023, 38(8): 743-748.
[6]	李志勇, 李星. 多模态超声在高血压患者大脑中动脉狭窄筛查中的临床价值[J]. 临床荟萃, 2023, 38(7): 613-617.
[7]	于晓东, 任晓艺, 刘美霞. 左西孟旦应用于机体重要器官疾病的研究进展[J]. 临床荟萃, 2023, 38(6): 573-576.
[8]	尚蒙, 王礼琳. 沙库巴曲/缬沙坦对慢性心力衰竭患者心律失常影响的研究进展[J]. 临床荟萃, 2023, 38(5): 459-464.
[9]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[10]	王凤华, 魏茂提. 干式桑拿疗法治疗慢性心力衰竭的研究进展[J]. 临床荟萃, 2023, 38(4): 369-372.
[11]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[12]	李娜娜, 江珊. 血清同型半胱氨酸、胱抑素C、超敏C-反应蛋白水平对急性ST段抬高型心肌梗死患者PCI术后并发心力衰竭的预测价值[J]. 临床荟萃, 2023, 38(2): 121-125.
[13]	郭雨, 李永东. ARNI在高血压治疗中的研究进展[J]. 临床荟萃, 2023, 38(2): 181-184.
[14]	刘奕, 崔坤, 刘畅, 赵浩天, 李丽, 薛红元. 血清分泌型卷曲蛋白5水平与原发性高血压患者早期肾损害的相关性[J]. 临床荟萃, 2023, 38(12): 1073-1077.
[15]	江吉, 朱小刚, 姜山, 达哇扎巴, 岑强. 世居高原高血压人群蛋白尿相关危险因素[J]. 临床荟萃, 2023, 38(12): 1086-1090.